This important study advances our understanding of developmental timing mechanisms by studying the cleavage, nuclear translocation, and oscillation of the transcription factor MYRF-1 (vertebrate MYRF) ...
Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophyBLA supported by positive pivotal HOPE-3 Phase 3 results, ...
Coherus Oncology (NASDAQ:CHRS) outlined progress on its transition to an “innovative oncology” company during its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results